RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, Thanks. Re-acquiring the Schizo and Depression rights would make Cortex considerably more attractive in a buyout, and if Cortex can get those rights back without any cash outlay (just a small future royalty stream to Merck), that would be great.

And even if there isn't a buyout, having all the rights back in house will give Cortex considerably more leeway in what they could offer prospective partners, indication-wise. At least Cortex would no longer be precluded from offering those indications once Merck is out of the picture.